Advertisement
AMRN vs MGNX
Which Stock Would AI Choose? Amarin Corporation (AMRN) vs. MacroGenics (MGNX) Stock Comparison
Key Takeaways
- AMRN (Amarin Corporation) is a commercial-stage cardiovascular drug company that has shifted to a cost-disciplined, cash-flow-positive model while revenue continues to decline on pricing and generic pressure.
- MGNX (MacroGenics) is a clinical-stage oncology biotech with strong 2026 momentum, multiple large-pharma partnerships, and a catalyst-rich pipeline balanced against ongoing net losses.
- AMRN offers a debt-free balance sheet and three consecutive quarters of positive operating cash flow; MGNX offers higher upside potential but greater volatility and binary clinical risk.
- MGNX has significantly outperformed AMRN over the past year on a relative performance basis, though AMRN has shown greater earnings and balance-sheet stability.
- For more information on each company's developments, visit the AMRN Major News and AMRN Today's Price Move pages, along with the MGNX Major News and MGNX Today's Price Move pages.
- To see how AI evaluates stocks like these, explore the curated Trending AI Robots.
Introduction
Investors weighing small- and mid-cap healthcare names often confront a core trade-off: the stability of an established commercial business versus the growth potential of an early-stage pipeline. AMRN and MGNX sit on opposite sides of that divide, making them a useful stock comparison for both momentum-oriented traders and value-focused investors. Amarin generates real revenue and cash flow from an approved cardiovascular therapy, while MacroGenics is still building toward commercialization through partnered oncology programs and clinical readouts. Understanding their relative performance, market positioning, and risk profiles helps clarify which type of capital each may attract in the current environment.
AMRN Overview and Recent Performance
Amarin Corporation commercializes Vascepa (known as Vazkepa in Europe), an icosapent ethyl therapy approved to reduce cardiovascular risk and treat severely elevated triglycerides. The company has faced sustained U.S. revenue pressure from generic competition and pricing dynamics. In response, management has executed a significant restructuring, cutting its workforce substantially and reducing operating expenses, which has narrowed operating losses and produced three consecutive quarters of positive operating cash flow. Amarin ended its most recent period with roughly $314 million in cash and investments and no debt.
Recent market activity has been shaped by several developments: a U.S. Supreme Court review of a Vascepa "skinny label" patent dispute, an expanded European commercialization partnership with Recordati spanning dozens of countries, and commentary positioning Vascepa within emerging high-triglyceride treatment strategies. Sentiment remains mixed, with some analysts citing disciplined cost control and cash generation as strengths, while others point to a single-product franchise and declining top-line revenue as persistent headwinds.
MGNX Overview and Recent Performance
MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based cancer therapies using its proprietary DART (Dual-Affinity Re-Targeting) and TRIDENT platforms. Its value is anchored in partnerships with Incyte, Sanofi, and Gilead, which support programs such as ZYNYZ (retifanlimab) and TZIELD (teplizumab) while funding a pipeline that includes lorigerlimab and the antibody-drug conjugate (ADC) candidates MGC026 and MGC028.
Over the past year, MGNX shares have delivered notable relative outperformance, aided by balance-sheet strengthening and pipeline progress. The company monetized a portion of its ZYNYZ royalties through a deal with Sagard and agreed to sell its manufacturing operations to Bora Pharmaceuticals, transactions that management says extend the cash runway toward 2028. Sentiment has also been supported by the lifting of a partial clinical hold on the LINNET study of lorigerlimab and several analyst price-target increases. These catalysts are offset by continued net losses and the inherent risk of clinical-stage drug development.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies drawn from a broader library of AI-powered bots covering thousands of tickers. Rather than listing every available bot, this section surfaces only those judged most suitable for current market conditions, helping traders filter signal from noise. The bots span varied trading styles, strategies, timeframes, and performance statistics, each managing its own set of tickers, so no two operate identically. If you are interested in how algorithmic systems assess names like AMRN and MGNX in real time, reviewing the Trending AI Robots can provide a practical starting point.
Head-to-Head Comparison
These two stocks differ sharply in business model and risk profile. Amarin is a revenue-generating, single-asset cardiovascular franchise focused on cash preservation, cost reduction, and international partner-driven distribution. Its growth is constrained by a mature U.S. market and an unresolved patent dispute, but its debt-free balance sheet and positive cash flow offer measurable downside support. MacroGenics, by contrast, is a multi-program oncology platform whose value depends on clinical data, partner milestones, and royalty streams rather than current product sales.
On momentum and market sentiment, MGNX has been the stronger performer, benefiting from partnership monetization, pipeline visibility, and constructive analyst revisions. AMRN has displayed less volatility but also weaker growth catalysts. In terms of sector exposure, both are healthcare names, yet Amarin carries commercial and reimbursement risk, while MacroGenics carries binary clinical and financing risk. Investors choosing between them are effectively choosing between near-term stability and longer-term optionality.
Tickeron AI Verdict
Based on observable trend consistency, relative momentum, and catalyst density, Tickeron's AI would likely lean toward MGNX in the current environment. Its stronger relative performance, multiple near-term clinical and partnership catalysts, and extended cash runway present a more favorable risk-reward setup from a momentum and positioning standpoint. That said, AMRN exhibits superior earnings stability and balance-sheet strength, making it comparatively lower-volatility. The assessment reflects probabilistic trend analysis rather than a definitive forecast, and either stock's outlook could shift quickly with new clinical, regulatory, or commercial data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a StrongBuy and MGNX is a StrongBuy.
AMRN's Stochastic Oscillator sits in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMRN's RSI Oscillator exited the oversold zone, 25 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +1.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in 183 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRN as a result. In 80 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for AMRN turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 43 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
AMRN broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMRN entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.553) is normal, around the industry mean (-1.421). P/E Ratio (-9.675) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (3.220) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (1.554) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
MGNX's Stochastic Oscillator dives oversold zone
The Stochastic Oscillator for MGNX moved into oversold territory on November 13, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MGNX's RSI Indicator exited the oversold zone, 23 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for MGNX just turned positive on November 10, 2026. Looking at past instances where MGNX's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.
Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 228 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In 81 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The 50-day moving average for MGNX moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.462) is normal, around the industry mean (3.498). P/E Ratio (-10.591) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AMRN | MGNX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 97 | |
PRICE GROWTH RATING 1..100 | 62 | 65 | |
P/E GROWTH RATING 1..100 | 26 | 10 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMRN's Valuation (63) in the Pharmaceuticals Other industry is in the same range as MGNX (88) in the Biotechnology industry. This means that AMRN’s stock grew similarly to MGNX’s over the last 12 months.
AMRN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as MGNX (100) in the Biotechnology industry. This means that AMRN’s stock grew similarly to MGNX’s over the last 12 months.
AMRN's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as MGNX (97) in the Biotechnology industry. This means that AMRN’s stock grew similarly to MGNX’s over the last 12 months.
AMRN's Price Growth Rating (62) in the Pharmaceuticals Other industry is in the same range as MGNX (65) in the Biotechnology industry. This means that AMRN’s stock grew similarly to MGNX’s over the last 12 months.
MGNX's P/E Growth Rating (10) in the Biotechnology industry is in the same range as AMRN (26) in the Pharmaceuticals Other industry. This means that MGNX’s stock grew similarly to AMRN’s over the last 12 months.
| AMRN | MGNX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 74% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 87% |
| Advances ODDS (%) | 5 days ago 74% | 5 days ago 84% |
| Declines ODDS (%) | 2 days ago 85% | 2 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRN’s FA Score shows that 1 FA rating(s) are green while MGNX’s FA Score has 1 green FA rating(s).
- AMRN’s FA Score: 1 green, 4 red.
- MGNX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRN’s TA Score shows that 3 TA indicator(s) are bullish while MGNX’s TA Score has 5 bullish TA indicator(s).
- AMRN’s TA Score: 3 bullish, 5 bearish.
- MGNX’s TA Score: 5 bullish, 4 bearish.
Price Growth
AMRN (@Pharmaceuticals: Major) experienced а -1.98% price change this week, while MGNX (@Biotechnology) price change was -5.58% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.36%. For the same industry, the average monthly price growth was +2.44%, and the average quarterly price growth was +6.83%.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
MGNX is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+1.36% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AMRN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with CNTB. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then CNTB could also see price increases.
| Ticker / NAME | Correlation To AMRN | 1D Price Change % | ||
|---|---|---|---|---|
| AMRN | 100% | -2.49% | ||
| CNTB - AMRN | 55% Loosely correlated | +1.79% | ||
| HRTX - AMRN | 44% Loosely correlated | -4.73% | ||
| MGNX - AMRN | 44% Loosely correlated | -3.93% | ||
| ALXO - AMRN | 43% Loosely correlated | -3.70% | ||
| ARWR - AMRN | 40% Loosely correlated | +1.34% | ||
More | ||||
MGNX and
Correlation & Price change
A.I.dvisor indicates that over the last year, MGNX has been loosely correlated with KRRO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MGNX jumps, then KRRO could also see price increases.
| Ticker / NAME | Correlation To MGNX | 1D Price Change % | ||
|---|---|---|---|---|
| MGNX | 100% | -3.93% | ||
| KRRO - MGNX | 45% Loosely correlated | -4.89% | ||
| AMRN - MGNX | 44% Loosely correlated | -2.49% | ||
| VYGR - MGNX | 42% Loosely correlated | +1.76% | ||
| ZVRA - MGNX | 38% Loosely correlated | -18.64% | ||
| MLTX - MGNX | 34% Loosely correlated | -2.87% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DIVO | 47.42 | 0.11 | +0.23% |
| Amplify CWP Enhanced Dividend Income ETF (DIVO) | |||
| XCOR | 85.46 | N/A | N/A |
| FundX ETF (XCOR) | |||
| LCO | 24.24 | N/A | N/A |
| LOGIQ Contrarian Opportunities ETF (LCO) | |||
| EKG | 22.48 | -0.23 | -1.03% |
| First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) | |||
| FNGO | 128.65 | -2.27 | -1.73% |
| MicroSectors FANG+ Index 2X Leveraged ETNs (FNGO) | |||